Rockwell Med (RWM) Stock Price & Analysis
RWM Stock Chart & Stats
- Day’s Range
- EUR 0.45 - EUR 0.45
- 52-Week Range
- EUR 0.45 - EUR 10.34
- Previous Close
- EUR 0.45
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 25.51M
- Enterprise Value
- EUR 10.93M
- Total Cash (Recent Filing)
- EUR 24.80M
- Total Debt (Recent Filing)
- EUR 13.93M
- Price to Earnings (P/E)
- ―
- Beta
- -0.29
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- -0.16
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Customer Diversification
Broad customer coverage across major dialysis providers and international markets reduces reliance on any single account and supports recurring product demand. New agreements and annual pricing provisions can improve revenue visibility while expanding the company’s commercial reach over the next several quarters.
Margin Expansion And Capacity
Improving gross margin alongside automation investment indicates that operational efficiencies are beginning to benefit the cost structure. Added capacity can support higher volumes and lower labor intensity, creating a durable foundation for further margin improvement as utilization increases.
Liquidity And Cash Generation
Positive quarterly operating cash flow and substantial liquidity give Rockwell Medical resources to fund operations, capacity expansion, and strategic initiatives without immediate dependence on external financing. This strengthens resilience while management works toward sustained profitability.
Bears Say
Persistent Unprofitability
Continued net losses and negative quarterly adjusted EBITDA show that operational progress has not yet translated into consistent earnings. Persistent unprofitability can limit internally funded growth and leaves future results dependent on further volume gains, cost reductions, and successful execution.
Revenue Volatility
The decline from the higher 2024 revenue base and flat first-half sales indicate that demand and purchasing patterns remain uneven. Revenue volatility makes fixed-cost absorption and margin expansion harder, increasing the execution burden needed to achieve the company’s sales and profitability targets.
New Device Execution Risk
The device initiative could broaden the product platform, but its early stage means commercial benefits are unproven and timing remains uncertain. Regulatory requirements and development costs could consume management attention or cash before the opportunity contributes meaningful revenue or profit.
RWM FAQ
What was Rockwell Med’s price range in the past 12 months?
What is Rockwell Med’s market cap?
When is Rockwell Med’s upcoming earnings report date?
How were Rockwell Med’s earnings last quarter?
Is Rockwell Med overvalued?
Does Rockwell Med pay dividends?
What is Rockwell Med’s EPS estimate?
How many shares outstanding does Rockwell Med have?
What happened to Rockwell Med’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Rockwell Med?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Rockwell Med
Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mark Strobeck
- Employees
- 157
- Website
- www.rockwellmed.com
- Address
- 30142 South Wixom road, Wixom, MI, 48393, US
Rockwell Med (RWM) Earnings & Revenues
RWM Company Deck
RWM Earnings Call
Earnings Call SentimentPositive
The call emphasized clear operational and financial progress: double-digit quarterly revenue growth, a 30% increase in quarterly gross profit, expanding gross margins (18% in Q2), positive operating cash flow (~$2.1M in Q2), strengthened liquidity ($24.8M), new customer agreements and capacity-adding automation. Offsetting these positives are that the company remains GAAP-loss-making (Q2 net loss $1.2M), adjusted EBITDA for the quarter remained negative $200K, six-month revenue was flat due to a prior-year purchasing distortion, and an early-stage device initiative and the recent reverse split present execution and perception risks. On balance, the improving top-line, margin expansion, positive cash generation, and reiterated guidance indicate momentum that materially outweighs the remaining short-term profitability and execution risks.
View all DE:RWM earnings summariesRWM Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 0 | 13 |
| Technical Analysis | 3 | 0 | 3 |
| Moving Averages | 2 | 0 | 10 |
